Horsburgh C R, Kirkpatrick C H
Am J Med. 1983 Jan 24;74(1B):23-9. doi: 10.1016/0002-9343(83)90511-9.
Our experience in the treatment of chronic mucocutaneous candidiasis with ketoconazole is reviewed. Of 21 patients, 15 have evidence of deficient cellular immunity and eight have endocrine abnormalities. Six patients had concurrent dermatophytosis or chromomycosis. All patients responded to treatment. Mucosal lesions improved in 6.7 +/- 0.5 days and cutaneous lesions responded to 22.7 +/- 5.1 days. The responses by infected nails were more variable (mean response time 92.4 +/- 14.4 days). Concurrent dermatophytoses did not prolong response times. Adverse effects were infrequent: one patient had drug-induced hepatitis and two patients became hypertensive. The relationship of hypertension to ketoconazole treatment is unclear. One patient was able to remain in remission after treatment was discontinued. Two patients had relapses while on treatment. Candida albicans isolated from these patients was highly resistant to ketoconazole in vitro. We conclude that ketoconazole is an effective and well-tolerated drug for the treatment of the infectious component of chronic mucocutaneous candidiasis.
我们回顾了使用酮康唑治疗慢性黏膜皮肤念珠菌病的经验。21例患者中，15例有细胞免疫缺陷的证据，8例有内分泌异常。6例患者同时患有皮肤癣菌病或着色芽生菌病。所有患者对治疗均有反应。黏膜病变在6.7±0.5天内改善，皮肤病变在22.7±5.1天内有反应。感染指甲的反应更具变化性（平均反应时间92.4±14.4天）。同时存在的皮肤癣菌病并未延长反应时间。不良反应很少见：1例患者出现药物性肝炎，2例患者血压升高。高血压与酮康唑治疗的关系尚不清楚。1例患者在停药后能够维持缓解状态。2例患者在治疗期间复发。从这些患者分离出的白色念珠菌在体外对酮康唑高度耐药。我们得出结论，酮康唑是治疗慢性黏膜皮肤念珠菌病感染部分的一种有效且耐受性良好的药物。
